Editas Medicine, Inc.
Короткая

$EDIT short under 70

Обновлено
EDIT up +140% over last 3 days. Pullback expected here. Gene editing is a hot topic at the moment, but price is absolutely overextended for company with less than 100M revenue annually. Long term huge long potential. Short term, short biased.
Сделка закрыта: достигнута тейк-профит цена
Fundamental AnalysisTrend Analysis

Мои профили:

Отказ от ответственности